TP53 and cancer: However, in STAD and HNSC, where patients with higher expression levels of TP53 have better OS or DFS prognoses than those with lower expression levels of TP53 (Figure 8), the association could be confounded by TP53 mutation status since TP53 shows significantly higher expression levels in TP53-wildtype cancers compared to TP53-mutated cancers in STAD and HNSC (Table 2), and TP53-wildtype cancers have better OS or DFS prognoses than TP53-mutated cancers in a number of cancer types including HNSC (Figure 6).